Aromatic/heterocyclic sulfonamides act as strong inhibitors of the zinc enzyme carbonic anhydrase (CA; EC 4.2.1.1), but the presently available compounds do not generally discriminate between the 14 isozymes isolated in higher vertebrates. Thus, clinically used drugs from this class of pharmacological agents show many undesired side effects due to unselective inhibition of all CA isozymes present in a tissue/organ. Here we propose a new approach for the selective in vivo inhibition of membrane-bound versus cytosolic CA isozymes with a new class of positively charged, membrane-impermeant sulfonamides. This approach is based on the attachment of trisubstituted-pyridinium-methylcarboxy moieties (obtained from 2,4,6-trisubstituted-pyrylium salt...
A series of 2-(hydrazinocarbonyl)-3-substitutedphenyl-1H-indole-5-sulfonamides possessing various 2-...
Except for sulfonamides, metal complexing anions represent the second class of inhibitors of the zin...
We report here a new drug design strategy for producing membrane-impermeant carbonic anhydrase (CA; ...
The inhibition of the newly discovered cytosolic carbonic anhydrase isozyme XIII (CA XIII) has been ...
A series of potent inhibitors of human carbonic anhydrase (CA) isoforms I and II has been prepared v...
The inhibition of the tumor-associated transmembrane carbonic anhydrase IX (CA IX) isozyme possessin...
At least 14 different carbonic anhydrase (CA, EC 4.2.1.1) isoforms were isolated in higher vertebrat...
A series of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides possessing various 2-, 3- or 4- su...
A series of new compounds was obtained by reaction of aromatic/heterocyclic sulfonamides incorporati...
A series of benzenesulfonamides incorporating pyrazole- and pyridazinecarboxamides decorated with se...
A series of benzenesulfonamides incorporating pyrazole- and pyridazinecarboxamides decorated with se...
A novel class of effective CAIs has been identified, starting from a very weak carbonic anhydrase in...
<p>Four groups of novel sulfonamide derivatives: (i) acetoxybenzamide, (ii) triacetoxybenzamide, (ii...
Carbonic Anhydrases (CAs) are pharmaceutically relevant targets for the treatment of several disease...
Carbonic Anhydrases (CAs) are pharmaceutically relevant targets for the treatment of several disease...
A series of 2-(hydrazinocarbonyl)-3-substitutedphenyl-1H-indole-5-sulfonamides possessing various 2-...
Except for sulfonamides, metal complexing anions represent the second class of inhibitors of the zin...
We report here a new drug design strategy for producing membrane-impermeant carbonic anhydrase (CA; ...
The inhibition of the newly discovered cytosolic carbonic anhydrase isozyme XIII (CA XIII) has been ...
A series of potent inhibitors of human carbonic anhydrase (CA) isoforms I and II has been prepared v...
The inhibition of the tumor-associated transmembrane carbonic anhydrase IX (CA IX) isozyme possessin...
At least 14 different carbonic anhydrase (CA, EC 4.2.1.1) isoforms were isolated in higher vertebrat...
A series of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides possessing various 2-, 3- or 4- su...
A series of new compounds was obtained by reaction of aromatic/heterocyclic sulfonamides incorporati...
A series of benzenesulfonamides incorporating pyrazole- and pyridazinecarboxamides decorated with se...
A series of benzenesulfonamides incorporating pyrazole- and pyridazinecarboxamides decorated with se...
A novel class of effective CAIs has been identified, starting from a very weak carbonic anhydrase in...
<p>Four groups of novel sulfonamide derivatives: (i) acetoxybenzamide, (ii) triacetoxybenzamide, (ii...
Carbonic Anhydrases (CAs) are pharmaceutically relevant targets for the treatment of several disease...
Carbonic Anhydrases (CAs) are pharmaceutically relevant targets for the treatment of several disease...
A series of 2-(hydrazinocarbonyl)-3-substitutedphenyl-1H-indole-5-sulfonamides possessing various 2-...
Except for sulfonamides, metal complexing anions represent the second class of inhibitors of the zin...
We report here a new drug design strategy for producing membrane-impermeant carbonic anhydrase (CA; ...